Drug Approvals International – Page 68 – All about Drugs Live by Dr Anthony Melvin Crasto

Upacicalcet sodium hydrate

Upacicalcet sodium hydrate, ウパシカルセトナトリウム水和物 CAS 2052969-18-1 1333218-50-0 free PMDA JAPAN APPROVED 2021/6/23, Upasita Calcium sensing receptor agonist (2S)-2-amino-3-[(3-chloro-2-methyl-5-sulfophenyl)carbamoylamino]propanoic acid Formula C11H13ClN3O6S. Na. xH2O OriginatorAjinomoto Pharma DeveloperSanwa Kagaku Kenkyusho ClassAmines; Chlorobenzenes; Propionic acids; Small molecules; Sulfonic acids; Toluenes Mechanism of ActionCalcium-sensing receptor agonists RegisteredSecondary hyperparathyroidism 25 Jun 2021Chemical structure information added 23 Jun 2021Sanwa Kagaku Kenkyusho and Kissei …

Imeglimin hydrochloride

Meglimin hydrochloride Twymeeg Formula C6H13N5. HCl CAS 775351-61-6 (HCl). , C6H14ClN5 191.66 CAS 775351-65-0, FREEFORM 155.20 Mol weight 191.6619 AntidiabeticAPPROVED PMDA JAPAN2021/6/23, イメグリミン塩酸塩 (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine DB12509 NCGC00378621-02 HY-14771 Q6003719 UNII-UU226QGU97 UU226QGU97 1,3,5-Triazine-2,4-diamine,1,6-dihydro-N,N,6-trimethyl-,(+)-(9CI) (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine Imeglimin [INN] Emd 387008 (R-imeglimin) HCl EMD-387008 Imeglimin is an experimental drug being developed as an oral anti-diabetic.[1][2] It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase …

CVnCoV, zorecimeran, CureVac COVID-19 vaccine

CVnCoV cas 2541470-90-8 An optimized, non-chemical modified mRNA encoding the prefusion-stabilized full-length spike protein of SARS-CoV-2 virus (Curevac) zorecimeran, CureVac COVID-19 vaccine CureVac/Bayer GSK NCT04674189 NCT04449276 NCT04515147 NCT04652102 EudraCT-2020-004066-19 mRNA-based vaccine PHASE 3 CVnCoV Humoral and cellular responses CD4+ T-cells, CD8+ T-cells N/A N/A Rhesus macaque [124] 124. Rauch S, Gooch K, Hall Y, Salguero FJ, …

Tucidinostat, Chidamide

Tucidinostat, Chidamide ツシジノスタット 2021/6/23 PMDA JAPAN APPROVED, Hiyasta Formula C22H19FN4O2 CAS 1616493-44-7 Mol weight 390.4103 Antineoplastic, Histone deacetylase inhibitor Chidamide (Epidaza) is a histone deacetylase inhibitor (HDI) developed in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3] Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), …

Isotretinoin

Isotretinoin Title: Isotretinoin CAS Registry Number: 4759-48-2 CAS Name: 13-cis-Retinoic acid Additional Names: 2-cis-vitamin A acid; neovitamin A acid Manufacturers’ Codes: Ro-4-3780 Trademarks: Accutane (Roche); Isotrex (Stiefel); Oratane (Douglas); Roaccutane (Roche) Molecular Formula: C20H28O2 Molecular Weight: 300.44 Percent Composition: C 79.95%, H 9.39%, O 10.65% Literature References: Naturally occurring metabolite of vitamin A, q.v.; inhibits sebum production. Prepn: C. D. Robeson et al., J. Am. Chem. Soc. 77, 4111 (1955). …

COVAX-19

Vaxine Pty Ltd company logo Vaxine’s promising new COVID-19 vaccine candidate A new multivalent COVID-19 vaccine developed by Australian company Vaxine to tackle the new virus variants could be game-changer in the fight against COVID-19 The world desperately needs a vaccine that blocks virus transmission and protects against all the variants. Covax-19 vaccine may soon …

Uprifosbuvir

Uprifosbuvir MK 3682, IDX 21437 ウプリホスブビル; Formula C22H29ClN3O9P CAS 1496551-77-9 Mol weight 545.9071 уприфосбувир [Russian] [INN] أوبريفوسبوفير [Arabic] [INN] 乌磷布韦 [Chinese] [INN] propan-2-yl (2R)-2-[[[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Isopropyl (2R)-2-{[(R)-{[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-3-hydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate IDX-21437, DB15206, SB18784, D10996, Q27281714 Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of Hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. It is currently in Phase III human clinical trials.[1][2][3] Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy …

ARCT-021 (LUNAR-COV19)

ARCT-021 (LUNAR-COV19) cas 2541451-24-3 A lipid-enabled and UnlockedNucleomonomer Agent modified RNA (LUNAR) of self-replicating RNA for vaccination against spike protein of SARS-CoV-2 (Arcturus) Self-replicating RNA vaccine Arcturus Therapeutics and Duke-NUS Medical School, Singapore OriginatorArcturus Therapeutics ClassCOVID-19 vaccines; RNA vaccines; Viral vaccines Mechanism of ActionImmunostimulants Orphan Drug StatusNo New Molecular EntityNo Available For LicensingYes – COVID 2019 …

DAPAGLIFLOZIN

DAPAGLIFLOZIN, BMS-512148 ダパグリフロジン; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Cas 461432-26-8 Molecular Formula: C21H25ClO6 Molecular Weight: 408.87 Dapagliflozin propandiol monohydrate; 960404-48-2 Molecular Weight 502.98 Formula C21H25ClO6•C3H8O2•H2O Bristol-Myers Squibb (Originator) AstraZeneca TYPE 2 DIABETES,SGLT-2 Inhibitors launched 2012, as forxiga in EU, FDA 2014, JAPAN PMDA 2014 Dapagliflozin propanediol monohydrate was first approved by European Medicine Agency (EMA) on November 12, 2012, then approved by the …

IIBR-100

IIBR-100 Brilife Recombinant vesicular stomatitis virus (rVSV) vaccine Israel Institute for Biological Research Hadassah Medical Center; Sheba Medical Center Hospital The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on …